| # | Title | Journal | Year | Citations |
|---|
| 1 | Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Lancet Oncology, The | 2009 | 6,451 |
| 2 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Lancet Oncology, The | 2009 | 5,104 |
| 3 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial | Lancet Oncology, The | 2012 | 4,943 |
| 4 | Definition and classification of cancer cachexia: an international consensus | Lancet Oncology, The | 2011 | 4,015 |
| 5 | Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial | Lancet Oncology, The | 2010 | 3,794 |
| 6 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study | Lancet Oncology, The | 2011 | 3,758 |
| 7 | Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China | Lancet Oncology, The | 2020 | 3,522 |
| 8 | International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma | Lancet Oncology, The | 2014 | 3,343 |
| 9 | Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial | Lancet Oncology, The | 2006 | 2,851 |
| 10 | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study | Lancet Oncology, The | 2009 | 2,404 |
| 11 | A review of human carcinogens—Part B: biological agents | Lancet Oncology, The | 2009 | 2,387 |
| 12 | Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study | Lancet Oncology, The | 2008 | 2,357 |
| 13 | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial | Lancet Oncology, The | 2015 | 2,353 |
| 14 | Nomograms in oncology: more than meets the eye | Lancet Oncology, The | 2015 | 2,187 |
| 15 | Global cancer statistics in the year 2000 | Lancet Oncology, The | 2001 | 2,158 |
| 16 | Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial | Lancet Oncology, The | 2009 | 2,128 |
| 17 | Global burden of cancers attributable to infections in 2008: a review and synthetic analysis | Lancet Oncology, The | 2012 | 2,094 |
| 18 | Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study | Lancet Oncology, The | 2010 | 2,093 |
| 19 | Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial | Lancet Oncology, The | 2005 | 2,092 |
| 20 | Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study | Lancet Oncology, The | 2017 | 2,058 |
| 21 | Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Lancet Oncology, The | 2014 | 1,932 |
| 22 | Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis | Lancet Oncology, The | 2009 | 1,920 |
| 23 | Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Lancet Oncology, The | 2010 | 1,915 |
| 24 | Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial | Lancet Oncology, The | 2012 | 1,879 |
| 25 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma | Lancet Oncology, The | 2016 | 1,866 |
| 26 | Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial | Lancet Oncology, The | 2015 | 1,861 |
| 27 | CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group | Lancet Oncology, The | 2006 | 1,840 |
| 28 | Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial | Lancet Oncology, The | 2018 | 1,816 |
| 29 | Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies | Lancet Oncology, The | 2011 | 1,778 |
| 30 | Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival | Lancet Oncology, The | 2010 | 1,773 |
| 31 | Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial | Lancet Oncology, The | 2014 | 1,740 |
| 32 | Hyperthermia in combined treatment of cancer | Lancet Oncology, The | 2002 | 1,714 |
| 33 | S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial | Lancet Oncology, The | 2008 | 1,667 |
| 34 | Global cancer transitions according to the Human Development Index (2008–2030): a population-based study | Lancet Oncology, The | 2012 | 1,626 |
| 35 | Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study | Lancet Oncology, The | 2015 | 1,625 |
| 36 | iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics | Lancet Oncology, The | 2017 | 1,612 |
| 37 | The present and future role of photodynamic therapy in cancer treatment | Lancet Oncology, The | 2004 | 1,581 |
| 38 | The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study | Lancet Oncology, The | 2015 | 1,574 |
| 39 | Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study | Lancet Oncology, The | 2014 | 1,554 |
| 40 | HPV-associated head and neck cancer: a virus-related cancer epidemic | Lancet Oncology, The | 2010 | 1,533 |
| 41 | Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data | Lancet Oncology, The | 2010 | 1,532 |
| 42 | Cancer-related inflammation and treatment effectiveness | Lancet Oncology, The | 2014 | 1,525 |
| 43 | Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial | Lancet Oncology, The | 2011 | 1,508 |
| 44 | Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial | Lancet Oncology, The | 2010 | 1,493 |
| 45 | FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial | Lancet Oncology, The | 2014 | 1,479 |
| 46 | Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial | Lancet Oncology, The | 2010 | 1,477 |
| 47 | Gastroenteropancreatic neuroendocrine tumours | Lancet Oncology, The | 2008 | 1,474 |
| 48 | Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis | Lancet Oncology, The | 2011 | 1,467 |
| 49 | Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial | Lancet Oncology, The | 2019 | 1,467 |
| 50 | Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial | Lancet Oncology, The | 2006 | 1,458 |
